Key Events This Week
7 Sep: Stock opens at Rs.4,594.25, declines 0.42%
8 Sep: Hits 52-week low of Rs.4,334 amid sector underperformance
9 Sep: Further 52-week low at Rs.4,178.05; technical momentum shifts bearish
10 Sep: New 52-week low of Rs.4,118.05 despite slight Sensex gain
11 Sep: Lowest close of week at Rs.4,062.05, marking six consecutive days of losses

Pfizer Ltd. is Rated Sell by MarketsMOJO
2026-09-12 10:10:26Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 September 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Six-Day Slide Pushes Pfizer Ltd. to 52-Week Low of Rs 4,054.55
2026-09-11 09:50:44For the sixth consecutive session, Pfizer Ltd. has closed lower, culminating in a fresh 52-week low of Rs 4,054.55 on 11 Sep 2026. This marks a 12.08% decline over the past six days, extending the stock’s underperformance amid a broader market that itself is struggling but not to the same extent.
Read full news article
Five Consecutive Losses Push Pfizer Ltd. to a New 52-Week Low
2026-09-09 09:58:34For the fifth straight session, Pfizer Ltd. closed lower, breaching its 52-week low at Rs 4,178.05 on 09 Sep 2026, marking a cumulative decline of 8.75% over this period amid broader market weakness.
Read full news article
Pfizer Ltd. Technical Momentum Shifts Amid Bearish Market Signals
2026-09-09 08:04:41Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating technical parameters and underwhelming returns relative to the Sensex, paints a challenging outlook for investors as of early September 2026.
Read full news article
Pfizer Ltd. Valuation Shifts Signal Growing Price Pressure Amid Sector Challenges
2026-09-09 08:00:45Pfizer Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a "very expensive" to an "expensive" rating. This change reflects a recalibration of price attractiveness amid recent market volatility and sector-wide pressures, with key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios signalling a less compelling entry point for investors.
Read full news article








